<DOC>
	<DOCNO>NCT00917358</DOCNO>
	<brief_summary>Interferon-based monotherapy consider effective treat acute hepatitis C ordinary patient . However , efficacy treatment evaluate prospective interventional study dialysis patient . The aim study evaluate efficacy peginterferon alfa-2a monotherapy 24 week special clinical setting , concomitantly evaluate retrospectively dialysis patient acute hepatitis C receive intervention reference .</brief_summary>
	<brief_title>Pegylated Interferon Alfa-2a Dialysis Patients With Acute Hepatitis C</brief_title>
	<detailed_description>Chronic viral hepatitis common dialysis patient , report prevalence annual incidence 3-80 % 2.9 % , respectively . The high incidence prevalence thse patient attribute potential nosocomial exposure hepatitis C virus dialysis , result high rate acute hepatitis C virus infection . It estimate 65-80 % patient acute hepatitis C evolve chronic infection , lead chronic hepatitis , cirrhosis , hepatic decompensation , hepatocellular carcinoma ( HCC ) . Currently , interferon pegylated interferon monotherapy remain effective treat acute hepatitis C ordinary patient , sustain virologic response ( SVR ) rate range 65-90 % 12-24 week therapy . However , data regard efficacy safety interferon-based monotherapy know till . Treatment weekly 135 pegylated interferon alfa-2a show superior safety thrice weekly 3 million unit ( MU ) standard interferon alfa-2a dialysis patient chronic hepatitis C. Under excellent safety profile treat dialysis patient low dose pegylated interferon alfa-2a , aim evaluate efficacy weekly 135 ug pegylated interferon alfa-2a total 24 week dialysis patient acute hepatitis C , also evaluate SVR rate retrospective chart review dialysis patient acute hepatitis C receive interferon-based therapy evaluate early intervention patient improve overall disease outcome .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age 1865 year old Creatinine clearance ( Ccr ) &lt; 10 ml/min/1.73 m2 AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &lt; 6 month define seroconversion Detectable serum quantitative HCVRNA ( Cobas Taqman HCV test , version 2 , Roche Diagnostics ) dynamic range 25391000000 IU/ml Severe anemia ( hemoglobin &lt; 10 g/dL ) hemoglobinopathy Neutropenia ( neutrophil count , &lt; 1,500/mm3 ) Thrombocytopenia ( platelet &lt; 90,000/ mm3 ) Coinfection HBV HIV Chronic alcohol abuse ( daily consumption &gt; 20 g/day ) Autoimmune liver disease Decompensated liver disease ( Child classification B C ) Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception Unwilling sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Interferon</keyword>
</DOC>